Blindness News and Research RSS Feed - Blindness News and Research

Tablet screening app can improve eye health outcomes in remote, underserved communities

Tablet screening app can improve eye health outcomes in remote, underserved communities

Using a tablet screening app could prove to be an effective method to aid in the effort to reduce the incidence of avoidable blindness in populations at high-risk for glaucoma with limited access to health care, according to a study released today at AAO 2014, the 118th annual meeting of the American Academy of Ophthalmology. [More]
New mutations in cat genome identified as causes of human eye diseases

New mutations in cat genome identified as causes of human eye diseases

Researchers from the University of Missouri and the 99 Lives Cat Genome Sequencing Initiative today announced groundbreaking discoveries of novel mutations in the cat genome found to correlate to two human eye diseases, retinitis pigmentosa and Leber's Congenital Amaurosis. [More]
Major scientific breakthrough in understanding retinal degenerative diseases that cause blindness

Major scientific breakthrough in understanding retinal degenerative diseases that cause blindness

An important scientific breakthrough by a team of IRCM researchers led by Michel Cayouette, PhD, is being published today by The Journal of Neuroscience. The Montréal scientists discovered that a protein found in the retina plays an essential role in the function and survival of light-sensing cells that are required for vision. [More]
Researchers awarded grant to develop non-invasive device to detect Human Cytomegalovirus

Researchers awarded grant to develop non-invasive device to detect Human Cytomegalovirus

Researchers from Cardiff and Swansea Universities have been awarded a grant of more than £323k to develop a new, non-invasive, low-cost, and easy to use point of care device to diagnose Human Cytomegalovirus (HCMV). [More]
New technique for treating eye cancer retinoblastoma

New technique for treating eye cancer retinoblastoma

Doctors at Cincinnati Children's Hospital Medical Center have developed a new technique for treating the eye cancer retinoblastoma to improve the odds for preventing eye loss, blindness or death in children with advanced forms of the disease. [More]
Research opens door to potential new treatments for peripheral artery disease

Research opens door to potential new treatments for peripheral artery disease

Researchers have developed a technique to jump-start the body's systems for creating blood vessels, opening the door for potential new treatments for diseases whose impacts include amputation and blindness. [More]
VisionCare's Implantable Miniature Telescope gets FDA approval for treating end-stage AMD

VisionCare's Implantable Miniature Telescope gets FDA approval for treating end-stage AMD

VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced the U.S. Food and Drug Administration approved the Implantable Miniature Telescope (by Dr. Isaac Lipshitz) for use in patients living with bilateral end-stage age-related macular degeneration who are age 65 or older. [More]
Eye Co receives patent for new class of eye disease drugs

Eye Co receives patent for new class of eye disease drugs

Australian ocular technology company Eye Co Pty Ltd has achieved a key commercial milestone, with a patent granted protecting its new class of eye disease drugs throughout the high value European market. [More]
Sightsavers launches biggest ever appeal to raise funds for sight-restoring surgeries

Sightsavers launches biggest ever appeal to raise funds for sight-restoring surgeries

A blind man's sight-restoring operation was broadcast live around the world at 1.30pm (BST) today from a hospital in Malawi. [More]
Health Canada approves Lucentis (ranibizumab) for myopic CNV

Health Canada approves Lucentis (ranibizumab) for myopic CNV

Novartis Pharmaceuticals Canada Inc. announced today that Lucentis (ranibizumab), the treatment for several major causes of vision loss, has been approved by Health Canada for the treatment of visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV). [More]
IRIDEX's new proprietary disposable delivery device granted U.S. patent

IRIDEX's new proprietary disposable delivery device granted U.S. patent

IRIDEX Corporation today announced that the United States Patent and Trademark Office granted the company a patent for a new proprietary disposable delivery device. [More]
Modified form of niclosamide drug may hold key to battling type 2 diabetes

Modified form of niclosamide drug may hold key to battling type 2 diabetes

Type 2 diabetes affects an estimated 28 million Americans according to the American Diabetes Association, but medications now available only treat symptoms, not the root cause of the disease. [More]
Blackflies infected with Onchocerca volvulus parasite may spread nodding syndrome

Blackflies infected with Onchocerca volvulus parasite may spread nodding syndrome

Despite decades of research, scientists have yet to pinpoint the exact cause of nodding syndrome (NS), a disabling disease affecting African children. A new report suggests that blackflies infected with the parasite Onchocerca volvulus may be capable of passing on a secondary pathogen that is to blame for the spread of the disease. New research is presented in the International Journal of Infectious Diseases. [More]
Placenta-derived cells are safe for MS patients

Placenta-derived cells are safe for MS patients

Patients with Multiple Sclerosis (MS) were able to safely tolerate treatment with cells cultured from human placental tissue, according to a study published today in the journal Multiple Sclerosis and Related Disorders. [More]
Treating prediabetes patients could help prevent severe complications associated with diabetes

Treating prediabetes patients could help prevent severe complications associated with diabetes

Doctors at three leading research institutions and the American Diabetes Association report that treating patients with prediabetes as if they had diabetes could help prevent or delay the most severe complications associated with this chronic disease, which affects about thirty million people in the United States. [More]
Researchers reveal why RB1 gene mutations primarily cause retinoblastomas in children

Researchers reveal why RB1 gene mutations primarily cause retinoblastomas in children

Retinoblastoma is a childhood retinal tumor usually affecting children one to two years of age. Although rare, it is the most common malignant tumor of the eye in children. [More]
Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

Celgene Global Health, a division of Celgene Corporation, and the Drugs for Neglected Diseases initiative strengthen their collaboration with a four-year Research Collaboration Agreement to identify and optimize new drug candidates for the treatment of neglected tropical diseases (NTDs). [More]
Dynamical glucometry may uncover new ways of understanding diabetes

Dynamical glucometry may uncover new ways of understanding diabetes

For millions of people in the United States living with Type 1 or Type 2 diabetes, measuring the daily rise and fall of blood glucose (sugar) is a way of life. [More]
Diabetes rates among U.S. adults stabilizing

Diabetes rates among U.S. adults stabilizing

Following a doubling of the incidence and prevalence of diabetes in the U.S. from 1990-2008, new data suggest a plateauing of the rate between 2008 and 2012 for adults, however the incidence continued to increase in Hispanic and non-Hispanic black adults, according to a study in the September 24 issue of JAMA. [More]
EYLEA Injection gets approval in Japan for treatment of myopic CNV

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV). [More]